Table 4 Summary of safety profile & adverse events across selected BsAb clinical trials.
From: Bispecific antibodies in the treatment of multiple myeloma
Study (Ref) | BsAb | No of patients | Follow up (median) | Hematologic AE Any grade/grade 3/4 | Infections (%) Any grade/grade 3/4 | Other AE (%) Any grade/grade 3/4 |
|---|---|---|---|---|---|---|
MajesTEC-1 [55] | Teclistamab | 165 | 23 months | Neutropenia – 71.5/65.5 Anemia – 90 /54.5% Thrombocytopenia -70 /2.4 Lymphopenia – 60/36.4 Leukopenia – 33/20 | 80/55.2 | CRS – 72.1/0.6 ICANS- 3/0 |
MagnetisMM-3 [62] | Elranatamab | 123 | 15 months | Neutropenia – 48.8/48.8 Anemia – 48.8/37.4 Thrombocytopenia -30.9/23.6 Lymphopenia – 26.8/25.2 | 70/46 | CRS – 58/0 ICANS – 3.4/0 |
MonumenTAL-1 [75] | Talquetamab 0.4 mg/kg QW 0.8 mg/kg Q2W | 288 143, 145 | 19 months 13 months | NA | 59/20 66/15 | CRS – 79.2/2 and 75/1 ICANS – 11 and 11 Skin – 56, 71 Hair/Nail – 54, 53 GI/Tongue-50, 48 |
NCT03275103 [77] | Cevostamab | 161 | 8.1 months | Neutropenia – 18.1/16.3 Anemia – 31.9/21.9 | 43/19 | CRS -81/1.2 ICANS -14/0.6 Raised ALT-15/6.9 |
RedirecTT-1 [41] | Teclistamab + Talquetamab | 63 | 14.4 months | Neutropenia – 76/75 Anemia – 60/43 | 79/38 | CRS- 81/3 ICANS -1 (Gr 1) |
LinkerMM-1 [66] | Linvoseltamab | 117 | Neutropenia – 38.5/37.6 Anemia – 38.5/30.8 Thrombocytopenia -17.9/14.5 Lymphopenia – 12.0/11.1 | 77.2/42.8 | CRS – 46.3/0.9 ICANS – 7.7 (Grade 3 ICANS in 3 pts) | |
NCT04557150 [76] | Forimtamig IV SC | 51 54 | 11.6 months 8 months | Neutropenia – 11. 8 & 16.7 Anemia – 13.7 & 5.2 Thrombocytopenia – 13.8 & 18.5 (Grade 3 and above) | 61/22 46/26 | CRS- 82.4/2 and 77.8/1 ICANS -9/1.9 (both cohorts) Skin – 72.5/11.8 & 81.5/14.8 Hair/Nail – 17.6/0 & 22.2/0 GI/Tongue-70.6/0 & 74.1/0 |
